BioWorld Asia

Jan. 31, 2007

Faith In Bio Market Pays Off With Europe's Largest Fund

LONDON - Abingworth Management closed Europe's largest ever life sciences venture fund, Abingworth Bioventures V, capping the oversubscribed fund at £300 million (US$586.9 million). (BioWorld International) Read More

GPC Biotech Banks $44M Toward Satraplatin Launch

Sleep-Inducing Drug Strategy Promises Some Sweet Dreams

Avesthagen Closes €25M Round, Proclaims Leadership In India

No Abstract Read More

Cellectis Launches IPO, Seeking €16M to €21M

No Abstract Read More

Anglo-Australian Partnership Seeks New Cancer Therapies

New Ethics Warning Issued On Nanomedicine In Europe

Plant Biotech Expert Attacks 'Dysfunctional' Regulations

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...